2022
Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2020
CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer
Nagaya N, Lee G, Horie S, Kim I. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer. Frontiers In Molecular Biosciences 2020, 7: 579874. PMID: 33195424, PMCID: PMC7593595, DOI: 10.3389/fmolb.2020.579874.Peer-Reviewed Original ResearchLymph node metastasisPrimary prostate cancerChemokines/receptorsMetastatic prostate cancerNode metastasisProstate cancerReceptor expressionMetastatic sitesChemokine/receptor axisMultivariate logistic regression analysisLog-rank test resultsLogistic regression analysisCancer Genome AtlasBone metastasesIndependent predictorsLymph nodesPostoperative recurrenceDistant metastasisCXCL10 expressionMRNA expression dataReceptor axisMetastasisTeam databaseLow expressionCancer progression
2019
MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE
Chandra* A, Assassi N, Kwon Y, Farber N, Kim I. MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000556802.43534.0b.Peer-Reviewed Original ResearchFactors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma.
Radadia K, Rivera-Nunez Z, Kim S, Farber N, Sterling J, Modi P, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma. Journal Of Clinical Oncology 2019, 37: 672-672. DOI: 10.1200/jco.2019.37.7_suppl.672.Peer-Reviewed Original ResearchClinical lymph nodesLymph node dissectionRenal cell carcinomaNational Cancer DatabaseTime of surgeryNode dissectionCell carcinomaTreatment centersPositive clinical lymph nodesNonmetastatic renal cell carcinomaAmerican Urological Association guidelinesNon-metastatic patientsClinical T stageEntire study populationPreoperative imaging modalitiesLogistic regression modelsGreatest predictorClinical characteristicsNodal involvementClinical stagingLymph nodesRegional lymphadenopathyT stageOpen surgeryRenal surgery
2016
Open versus robotic cystectomy: Comparison of outcomes
Davis R, Farber N, Tabakin A, Kim I, Elsamra S. Open versus robotic cystectomy: Comparison of outcomes. Investigative And Clinical Urology 2016, 57: s36-s43. PMID: 27326405, PMCID: PMC4910765, DOI: 10.4111/icu.2016.57.s1.s36.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical cystectomyRadical cystectomyMuscle-invasive bladder cancerExtrapelvic lymph nodesFaster gastrointestinal recoveryLower narcotic requirementLymph node yieldInvasive bladder cancerPositive surgical marginsCurrent gold standard treatmentNumber of patientsGold standard treatmentComparison of outcomesSuperior patient outcomesRobotic surgical techniquesNarcotic requirementsPerioperative advantagesTransfusion rateGastrointestinal recoveryOncologic outcomesUrinary continenceBlood lossPostoperative qualityDistant metastasisLymph nodes
2013
Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study
Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal Of Urology 2013, 190: 527-534. PMID: 23485503, DOI: 10.1016/j.juro.2013.02.073.Peer-Reviewed Original ResearchConceptsProstatic anterior fat padAnterior fat padLymph node metastasisMetastatic diseaseLymph nodesNode metastasisFat padPathological analysisMost patientsConcomitant pelvic lymph node dissectionPelvic lymph node dissectionBiochemical recurrence-free survivalAdjuvant/salvage therapyLymph node dissectionCharacteristics of patientsHigh-risk featuresTertiary care centerRecurrence-free survivalMulti-institutional studyPerioperative characteristicsSalvage therapyAdjuvant therapyNode dissectionAndrogen ablationClinical outcomes
2011
Pathologic implications of prostatic anterior fat pad
Jeong J, Choi E, Kang D, Ercolani M, Lee D, Kim W, Kim I. Pathologic implications of prostatic anterior fat pad. Urologic Oncology Seminars And Original Investigations 2011, 31: 63-67. PMID: 21396837, DOI: 10.1016/j.urolonc.2010.09.003.Peer-Reviewed Original ResearchConceptsProstatic anterior fat padRobot-assisted radical prostatectomyMetastatic prostate cancerLymph nodesProstate cancerAnterior fat padPSA levelsRadical prostatectomyLymphoid tissuePathologic analysisFat padPathologic implicationsSignificant pathologic differencesHigh-risk featuresPelvic lymph nodesRetrospective chart reviewLymph node statusProstate cancer patientsChart reviewConsecutive patientsPathologic stagingRoutine excisionNode statusBiochemical recurrenceCancer patients
2001
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma
Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92: 2985-2992. PMID: 11753975, DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsMuscle-invasive transitional cell carcinomaTransitional cell carcinomaT1 transitional cell carcinomaPreoperative plasma levelsPlasma TGFDisease recurrenceIndependent predictorsLymph nodesClinical outcomesPlasma levelsBladder carcinomaGrowth factorDisease-specific mortalityDisease-specific survivalRegional lymph nodesSubgroup of patientsStrong independent predictorGrowth factor-β1Intravesical immunoCarcinoma metastaticLymphovascular invasionSpecific survivalRadical cystectomyPathologic featuresCell carcinomaPreoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.Peer-Reviewed Original ResearchConceptsProstate cancer metastaticPlasma TGFPreoperative plasma levelsRegional lymph nodesRadical prostatectomyCancer metastaticPSA progressionLymph nodesGleason sumPlasma levelsGrowth factorLocal-only failureOccult metastatic diseasePathologic Gleason sumPostoperative multivariate analysisOrgan-confined diseaseSurgical margin statusLymph node metastasisBiopsy Gleason sumRadical prostatectomy patientsProstate cancer invasionMetastatic diseaseBone metastasesConsecutive patientsMargin status